Abstract: This disclosure relates to protease-cleavable cytokine prodrugs. In some embodiments, the prodrugs comprise a targeting sequence. In some embodiments, the prodrugs comprise a pharmacokinetic modulator.

Abstract: This disclosure relates to protease-cleavable IL-2 cytokine prodrugs. In some embodiments, the prodrugs comprise a pharmacokinetic modulator.

Abstract: The present invention relates to a golf head and a welding method thereof. In the welding method of the invention, a metal plate is disposed in an opening of a metal body, wherein the shape of the metal plate matches that of the opening. Subsequently, a first electrode and a second electrode contact a back surface of the metal body and a top surface of the metal plate respectively, wherein the shapes of the first electrode and the second electrode match those of the back surface and the top surface respectively. Finally, the first electrode and the second electrode output a current so as to weld the metal body and the metal plate by a resistance welding process. By utilizing the welding method, the welding speed can be significantly increased so as to increase the yield, and the welded joint can be stronger. Furthermore, the welded golf head has a high flatness so that the following manufacturing cost can be decreased.

Abstract: Methods for generating F(ab?)2 fragments from antibodies using thermolysin as well as F(ab?)2 fragments and compositions comprising F(ab?)2 fragments generated by the method are described.

Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.

Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.

Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind Dkk-1 polypeptides. The subject antibodies and fragments bind with high affinity to a conformational epitope located in the carboxy region of the Dkk-1 protein. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases including bone disorders, inflammatory diseases, neurological diseases, ocular diseases, renal diseases, pulmonary diseases and skin diseases are also disclosed.

Abstract: The present invention relates to stem cell factor analog polypeptide compositions, and vectors, host cells, and processes for recombinant DNA production of the present stem cell factor analogs. Pharmaceutical compositions and methods of use are also disclosed.

Abstract: Norleucine incorporation into recombinant gene products may be inhibited by culturing the cells expressing the gene products in media comprising a high level of leucine and/or methionine, or by expressing the gene products in a leu mutant. Norleucine incorporation in recombinant gene products may be promoted by culturing the cells expressing the gene products in media comprising norleucine or deficient in leucine and/or methionine. For example, norleucine analogs of IL-2, GCSF, .gamma.-interferon and .alpha.-consensus interferon may be produced in this way.